|
|
|
|
|
|
|
|
|
|
CUDC-427 Phase 1 Trial Placed on Partial Clinical Hold by FDA
"The current open-label, single-agent, dose escalation Phase 1 study of CUDC-427 was initiated in the third quarter of 2013 in patients with advanced and refractory solid tumors or lymphomas."
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.